Intra-Cellular Therapies Inc (NASDAQ:ITCI)‘s stock had its “outperform” rating reissued by research analysts at Leerink Swann in a research report issued on Monday.

ITCI has been the subject of a number of other reports. Cantor Fitzgerald assumed coverage on shares of Intra-Cellular Therapies in a research note on Friday, December 16th. They set an “overweight” rating and a $32.00 price objective for the company. Cowen and Company reissued a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, March 1st. Zacks Investment Research cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, December 20th. Piper Jaffray Companies reissued an “overweight” rating and set a $22.00 price objective on shares of Intra-Cellular Therapies in a research note on Thursday, February 23rd. Finally, BTIG Research assumed coverage on shares of Intra-Cellular Therapies in a research note on Thursday, December 22nd. They set a “buy” rating and a $44.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $35.25.

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI) traded down 2.11% on Monday, reaching $14.84. The company’s stock had a trading volume of 265,389 shares. Intra-Cellular Therapies has a 52 week low of $10.43 and a 52 week high of $45.20. The stock’s market capitalization is $644.20 million. The firm has a 50 day moving average price of $13.95 and a 200 day moving average price of $18.50.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.77) by $0.13. During the same quarter in the previous year, the firm earned ($0.67) EPS. On average, equities analysts anticipate that Intra-Cellular Therapies will post ($3.28) EPS for the current year.

Your IP Address:

In other Intra-Cellular Therapies news, Chairman Sharon Mates sold 4,081 shares of Intra-Cellular Therapies stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of $16.55, for a total value of $67,540.55. Following the completion of the sale, the chairman now directly owns 1,088,707 shares of the company’s stock, valued at approximately $18,018,100.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael Halstead sold 1,601 shares of Intra-Cellular Therapies stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $16.55, for a total transaction of $26,496.55. Following the completion of the sale, the senior vice president now directly owns 21,506 shares of the company’s stock, valued at $355,924.30. The disclosure for this sale can be found here. Insiders sold a total of 7,600 shares of company stock valued at $125,838 over the last ninety days. 19.80% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the company. Spark Investment Management LLC purchased a new stake in Intra-Cellular Therapies during the third quarter valued at approximately $3,046,000. Tocqueville Asset Management L.P. boosted its stake in Intra-Cellular Therapies by 6.5% in the third quarter. Tocqueville Asset Management L.P. now owns 91,775 shares of the biopharmaceutical company’s stock valued at $1,399,000 after buying an additional 5,600 shares during the last quarter. Bogle Investment Management L P DE purchased a new stake in Intra-Cellular Therapies during the fourth quarter valued at approximately $6,843,000. BB Biotech AG boosted its stake in Intra-Cellular Therapies by 92.9% in the third quarter. BB Biotech AG now owns 1,350,000 shares of the biopharmaceutical company’s stock valued at $20,574,000 after buying an additional 650,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC boosted its stake in Intra-Cellular Therapies by 411.3% in the third quarter. Essex Investment Management Co. LLC now owns 84,488 shares of the biopharmaceutical company’s stock valued at $1,288,000 after buying an additional 67,964 shares during the last quarter. 64.02% of the stock is owned by hedge funds and other institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Ratings for Intra-Cellular Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc and related companies with MarketBeat.com's FREE daily email newsletter.